CONTENT VALIDITY OF FACT-GP5 TO ASSESS TREATMENT TOLERABILITY IN PARTICIPANTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR-NAIVE, RET-MUTANT MEDULLARY THYROID CANCER: QUALITATIVE INTERVIEW SUB-STUDY OF THE LIBRETTO-531 TRIAL

被引：0

作者：

Altman, D. ^{[1
]}

Choi, J. ^{[1
]}

Elisei, R. ^{[2
]}

Jarzab, B. ^{[3
]}

Wadsley, J. ^{[4
]}

Gilligan, A. ^{[5
]}

Maeda, P. ^{[6
]}

Bourke, S. ^{[6
]}

Payakachat, N. ^{[7
]}

机构：

[1] Modus Outcomes, Cambridge, MA USA

[2] Univ Pisa, Pisa, Tuscany, Italy

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Gliwice Branch, Gliwice, Poland

[4] Weston Pk Canc Ctr, Sheffield, S Yorkshire, England

[5] Eli Lilly & Co, Roanoke, TX USA

[6] Eli Lilly & Co, Indianapolis, IN USA

[7] Eli Lilly & Co, Little Rock, AR 72223 USA

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCR200

引用

页码：S333 / S334

页数：2